A clinical trial studying afamelanotide was updated on July 27, 2026. The trial, titled "Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients," is registered as NCT06388642.
The study is listed as Phase 1/Phase 2 and its status has been recorded as completed. The trial focused on pharmacokinetics of afamelanotide in patients with erythropoietic protoporphyria.
No results, outcomes, or efficacy data are included in this update. The available information reflects only the change in trial status and the classification of the study phase.
Afamelanotide is an approved compound. This brief reports solely on the trial status change as recorded in the update and does not characterize or interpret any clinical findings, since none were provided in the source data.
Readers seeking additional background on this compound can consult the afamelanotide overview for further context.